Opinion|Videos|September 10, 2024
Closing
Fact checked by: Dean Elterman, MD, MSc
Dean Elterman, MD, discusses how minimally invasive surgical therapies (MIST) are increasingly integrated into the treatment landscape for benign prostatic hyperplasia (BPH), addressing unmet needs and offering new options, while also highlighting ongoing trials and investigations that aim to further refine these approaches.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do minimally invasive surgical therapies (MIST) options fit into the evolving landscape of treatments for benign prostate dysplasia; why should urologists consider MIST options for their patients?
- What unmet needs remain in the treatment of BPH, and are there any current trials/investigations in these topics?
Advertisement
Related to this article
The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
Isaac Y. Kim, MD, PhD, MBA, joins to discuss the evolving data surrounding neoadjuvant therapy before radical prostatectomy in prostate cancer.
The safety and efficacy of vibegron are supported by data from the phase 3 COURAGE and EMPOWUR trials.
A decision is expected by the fourth quarter of 2026.
Marian Cuello joins to discuss sexual wellness and the importance of normalizing conversations about sexual health for all individuals.
Eugene Cone, MD, discusses SWOG S1602 findings comparing Tokyo-172 and TICE BCG and the potential role of alternative BCG strains in NMIBC
EG110A is an investigational DNA medicine under development for neurogenic detrusor overactivity with urinary incontinence.
Juan Gómez-Rivas, MD, discusses barriers to PSMA-PET imaging and how disparities in access may affect prostate cancer staging and treatment planning.
The clearance expands access to the LigaSure vessel-sealing technology within robotic surgical workflows.
Advertisement
Advertisement
Trending on Urology Times
1
CHMP recommends perioperative enfortumab vedotin plus pembrolizumab for MIBC
2
FDA grants RMAT designation to EG110A for neurogenic detrusor overactivity
3
Topical sildenafil cream associated with lower systemic exposure vs oral sildenafil
4
FAQs: The 2026 AUA Guideline on Medical Management of Kidney Stones
5